Patents by Inventor Annika Sonntag

Annika Sonntag has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190062401
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 28, 2019
    Inventors: Annika SONNTAG, Toni WEINSCHENK, Andrea MAHR, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Publication number: 20190040115
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 7, 2019
    Inventors: Annika SONNTAG, Toni WEINSCHENK, Andrea MAHR, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Publication number: 20190040114
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 7, 2019
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20190040112
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Application
    Filed: October 16, 2018
    Publication date: February 7, 2019
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20190040113
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 7, 2019
    Inventors: Annika SONNTAG, Toni WEINSCHENK, Andrea MAHR, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Patent number: 10035838
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: July 31, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20180193439
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Application
    Filed: December 20, 2017
    Publication date: July 12, 2018
    Inventors: ANNIKA SONNTAG, TONI WEINSCHENK, ANDREA MAHR, OLIVER SCHOOR, JENS FRITSCHE, HARPREET SINGH
  • Patent number: 9901629
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: February 27, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20170326216
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Application
    Filed: June 30, 2017
    Publication date: November 16, 2017
    Inventors: ANNIKA SONNTAG, TONI WEINSCHENK, ANDREA MAHR, OLIVER SCHOOR, JENS FRITSCHE, HARPREET SINGH
  • Publication number: 20170305991
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 26, 2017
    Inventors: ANNIKA SONNTAG, TONI WEINSCHENK, ANDREA MAHR, OLIVER SCHOOR, JENS FRITSCHE, HARPREET SINGH
  • Publication number: 20140188450
    Abstract: The present invention relates to a method (2) for predicting the response of a structure (4), of a group of structures (16) and/or of a network profile (18), as a result to a perturbation, in particular by an agent (6) or a combination of agents (8) through modelling, optimizing, paramaterizing, testing and/or validating a dynamic network or network perturbations.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 3, 2014
    Inventors: Kathrin Thedieck, Annika Sonntag, Daryl Shanley, Piero Dalle Pezze